Managing Small Airway Disease in Patients with Severe Asthma: Transitioning from the “Silent Zone” to Achieving “Quiet Asthma”
Authors:
- Giovanna Elisiana CarpagnanoGCGiovanna Elisiana Carpagnano
- Andrea PortacciAPAndrea Portacci
- Silvano DragonieriSilvano Dragonieri
- Francesca MontagnoloFMFrancesca Montagnolo
- Ilaria IorilloIIIlaria Iorillo
- Ernesto LulajELErnesto Lulaj
- Leonardo MaselliLMLeonardo Maselli
- Enrico BuonamicoEBEnrico Buonamico
- Vitaliano Nicola QuarantaVitaliano Nicola Quaranta
Open Access
- 17 April 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (8) , 2320
Abstract
Background/Objectives: Several studies have demonstrated the positive clinical and functional impact of adding Long-Acting Muscarinic Antagonist (LAMA) to Inhaled Corticosteroids (ICS) and Long-Acting Beta-Agonists (LABA) therapy in the treatment of severe asthma. Aim and objectives: To demonstrate that treating Small Airways Disease (SAD) in severe asthma patients who are candidates for biologics can improve respiratory symptoms, lung function, and airways inflammation, potentially avoiding or delaying the use of biological therapy. Methods: Thirty-two severe asthma patients with SAD were transitioned from separate inhalers for ICS/LABA and LAMA to extrafine single-inhaler beclomethasone, formoterol, and glycopyrronium. None of these patients underwent biological therapy before the study. Follow-up evaluations were conducted at baseline (T0) and three months after initiation (T3). Assessments included clinical evaluations, spirometry, oscillometry, and inflammation markers. Results: Transitioning to single-inhaler triple therapy from T0 to T3 resulted in significant improvements in Asthma Control Test (ACT) and SAD parameters, including increased Forced Expiratory Volume in the mid-range of lung capacity and improved airway resistance and reactance measurements using impulse oscillometry. A significant reduction in airway inflammation was evidenced by lower levels of Fractional Exhaled Nitric Oxide 350 (FeNO 350) (p < 0.001 for all). Conclusions: Adopting a single-inhaler triple therapy notably enhanced clinical control and small airway function in patients with severe asthma and SAD, supporting the positive impact of target-therapy for the achievement of a stable state termed “Quiet Asthma”.Keywords
This publication has 34 references indexed in Scilit:
- Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi ConsensusThe Journal of Allergy and Clinical Immunology: In Practice, 2023
- Super-Responders to Biologic Treatment in Type 2–High Severe Asthma: Passing Fad or a Meaningful Phenotype?The Journal of Allergy and Clinical Immunology: In Practice, 2023
- Understanding the role of long-acting muscarinic antagonists in asthma treatmentAnnals of Allergy, Asthma & Immunology, 2022
- Defining a Severe Asthma Super-Responder: Findings from a Delphi ProcessThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- Triple vs Dual Inhaler Therapy and Asthma Outcomes in Moderate to Severe AsthmaJAMA, 2021
- An expert consensus framework for asthma remission as a treatment goalJournal of Allergy and Clinical Immunology, 2020
- Cost-effectiveness and comparative effectiveness of biologic therapy for asthmaAnnals of Allergy, Asthma & Immunology, 2019
- The prevalence of small airways disease in adult asthma: A systematic literature reviewRespiratory Medicine, 2016
- Interaction between corticosteroids and muscarinic antagonists in human airwaysPulmonary Pharmacology & Therapeutics, 2016
- Muscarinic Receptor Antagonists: Effects on Pulmonary Function2011